Helmut-Bauer-Nachwuchspreis 2011 für Multiple-Sklerose-ForschungDMSG Multiple Sklerose NachrichtenDie Arbeit von Dr. Simone Wüst wurde prämiert, weil sie im Detail die Wirkung des monoklonalen Antikörpers Daclizumab bei der T-Zellaktivierung Der 23…
George Scangos – The 25 most influential people in biopharma todayFierceBiotechThe Weston, MA-based company's stock took off last year, fueled by positive data on key experimental therapies such as the multiple sclerosis pill BG-12 and the long-act…
Biogen Idec's CEO Discusses Q4 2011 Results – Earnings Call TranscriptSeeking AlphaSELECT, the first of 2 registrational trials for Daclizumab, showed impressive clinical results in 2011 and supported the continuation of the second registrational s…
The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs …Sacramento BeeAbbott Labs, along with partner Biogen (Nasdaq: BIIB), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRM…
The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs …NASDAQAbbott Labs, along with partner Biogen ( BIIB ), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple sclerosis ( RRMS ). Abbott L…
The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs …PR Newswire (press release)Abbott Labs, along with partner Biogen (Nasdaq: BIIB), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple s…
Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth …MarketWatch (press release)Presented New Daclizumab Data at Multiple Sclerosis Congress Announced with our partner company Biogen Idec additional results from the SELECT Phase 2…
Newly Released BioTrends Chart Audit Report Identifies Variations in Treatment …EON: Enhanced Online News (press release)Patient profiles for the seven DMAs in late clinical development (alemtuzumab, BG-12, teriflunomide, laquinimod, PEG-Avonex, dacl…
Newly Released BioTrends Chart Audit Report Identifies Variations in Treatment …MarketWatch (press release)Patient profiles for the seven DMAs in late clinical development (alemtuzumab, BG-12, teriflunomide, laquinimod, PEG-Avonex, daclizumab, ocreli…
Neutral on Biogen – Analyst BlogNASDAQOther interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs ( ABT ), and PEGylated interferon. Biogen's pipeline also has candidates for other ailments…